Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Giunti, Serena ^a   Antonelli, Alessandro ^b   Amorosi, Andrea ^a   Santarpia, Libero ^c  

^a Centro Oncologico Fiorentino   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANGIOPEPTIN; BORTEZOMIB; CABOZANTINIB; CAPECITABINE; CELECOXIB; CHIR 265; DACARBAZINE; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; IMATINIB; LITHIUM CHLORIDE; METFORMIN; MOTESANIB; NAVELBINE; OCTREOTIDE; PASIREOTIDE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; ROFECOXIB; SELUMETINIB; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; EGFR GENE; GENE MUTATION; HUMAN; IC 50; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RET GENE; REVIEW; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 84874824354     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/803171     Document Type: Review

References (115)

1. Antonelli A., Martina Ferrari S., Fallahi P., Minuto M., Corrado A., Bruno R., Miccoli P., Medullary thyroid cancer: new targeted molecular therapies. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 2010 4 1 10 14 2-s2.0-77951110391 10.2174/187221410790226765
2. Ball D. W., Baylin S. B., De Butros A. C., Braverman L. E., Utiger R. D., Medullary thyroid carcinoma. Werner and Ingbar's the Thyroid 2000 8th Philadelphia, Pa, USA Lippincott Williams and Wilkins 930 943
3. Pinchera A., Ernest l. M., Ujjal C. H., Mallick K., Kendall-Taylor P., Medullary thyroid cancer: diagnosis and treatment. Practical Management of Thyroid Cancer 2006 London, UK Springer-Verlag Ltd. 255 280
4. Roman S., Lin R., Sosa J. A., Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006 107 9 2134 2142 2-s2.0-33750509391 10.1002/cncr.22244 (Pubitemid 44665646)
5. Santarpia L., Ye L., Gagel R. F., Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. Journal of Internal Medicine 2009 266 1 99 113 2-s2.0-66849128386 10.1111/j.1365-2796.2009. 02112.x
6. Brassard M., Rondeau G., Role of vandetanib in the management of medullary thyroid cancer. Biologics 2012 6 59 66
7. Ye L., Santarpia L., Gagel R. F., The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocrine Reviews 2010 31 4 578 599 2-s2.0-77955393886 10.1210/er.2009-0031
8. Husain M., Alsever R. N., Lock J. P., Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Hormone Research 1978 9 1 22 25 2-s2.0-0017920927 (Pubitemid 8233406)
9. Droz J. P., Schlumberger M., Rougier P., Ghosn M., Gardet P., Parmentier C., Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990 76 5 480 483 2-s2.0-0025650377
10. Scherübl H., Raue F., Ziegler R., Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. Journal of Cancer Research and Clinical Oncology 1990 116 1 21 23 2-s2.0-0025322092 (Pubitemid 20132849)
11. Antonelli A., Fallahi P., Ferrari S. M., RET TKI: potential role in thyroid cancers. Current Oncology Reports 2012 14 2 97 104 10.1007/s11912-012- 0217-0
12. Lodish M. B., Stratakis C. A., RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Review of Anticancer Therapy 2008 8 4 625 632 2-s2.0-43049161065 10.1586/14737140.8.4.625 (Pubitemid 351818356)
13. Airaksinen M. S., Saarma M., The GDNF family: signalling, biological functions and therapeutic value. Nature Reviews Neuroscience 2002 3 5 383 394 2-s2.0-0036581222 10.1038/nrn812 (Pubitemid 135706635)
14. Drosten M., Pützer B. M., Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nature Clinical Practice Oncology 2006 3 10 564 574 2-s2.0-33750596636 10.1038/ncponc0610 (Pubitemid 44781726)
15. Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., Vasko V., El-Naggar A. K., Xing M. M., Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Journal of Clinical Endocrinology and Metabolism 2008 93 8 3106 3116 2-s2.0-49249127826 10.1210/jc.2008-0273
16. Mitsiades C. S., Kotoula V., Poulaki V., Sozopoulos E., Negri J., Charalambous E., Fanourakis G., Voutsinas G., Tseleni-Balafouta S., Mitsiades N., Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. Journal of Clinical Endocrinology and Metabolism 2006 91 9 3662 3666 2-s2.0-33748741639 10.1210/jc.2006-0055 (Pubitemid 44402152)
17. Erovic B. M., Kim D., Cassol C., Prognostic and predictive markers in medullary thyroid carcinoma. Endocrine Pathology 2012 23 4 232 242 10.1007/s12022-012-9225-8
18. Rodríguez-Antona C., Pallares J., Montero-Conde C., Inglada-Pérez L., Castelblanco E., Landa I., Leskelä S., Leandro-García L. J., López-Jiménez E., Letón R., Cascón A., Lerma E., Martin M. C., Carralero M. C., Mauricio D., Cigudosa J. C., Matias-Guiu X., Robledo M., Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocrine-Related Cancer 2010 17 1 7 16 2-s2.0-77449155462 10.1677/ERC-08-0304
19. Croyle M., Akeno N., Knauf J. A., Fabbro D., Chen X., Baumgartner J. E., Lane H. A., Fagin J. A., RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research 2008 68 11 4183 4191 2-s2.0-49249084044 10.1158/0008-5472.CAN-08-0413
20. Capp C., Wajner S. M., Siqueira D. R., Brasil B. A., Meurer L., Maia A. L., Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010 20 8 863 871 2-s2.0-77955298957 10.1089/thy.2009.0417
21. Kerbel R. S., Tumor angiogenesis. New England Journal of Medicine 2008 358 19 2039 2049 2-s2.0-43249095919 10.1056/NEJMra0706596 (Pubitemid 351656458)
22. Gómez K., Varghese J., Jiménez C., Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. Journal of Thyroid Research 2011 2011 815826 10.4061/2011/815826
23. Jeffers M., Fiscella M., Webb C. P., Anver M., Koochekpour S., Vande Woude G. F., The mutationally activated Met receptor mediates motility and metastasis. Proceedings of the National Academy of Sciences of the United States of America 1998 95 24 14417 14422 2-s2.0-0032564341 10.1073/pnas.95.24.14417 (Pubitemid 28549382)
24. Papotti M., Olivero M., Volante M., Negro F., Prat M., Comoglio P. M., Direnzo M. F., Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocrine Pathology 2000 11 1 19 30 2-s2.0-0034124626 (Pubitemid 30307941)
25. Wasenius V. M., Hemmer S., Karjalainen-Lindsberg M. L., Nupponen N. N., Franssila K., Joensuu H., MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. American Journal of Surgical Pathology 2005 29 4 544 549 2-s2.0-15744373856 10.1097/01.pas.0000156103.37756.e2 (Pubitemid 40411189)
26. Ivan M., Bond J. A., Prat M., Comoglio P. M., Wynford-Thomas D., Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997 14 20 2417 2423 2-s2.0-0031006805 10.1038/sj.onc.1201083 (Pubitemid 27268160)
27. Bernard R. S., Zheng L., Liu W., Winer D., Asa S. L., Ezzat S., Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005 146 3 1145 1153 2-s2.0-14244249958 10.1210/en.2004-1134 (Pubitemid 40289303)
28. Ezzat S., Huang P., Dackiw A., Asa S. L., Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research 2005 11 3 1336 1341 2-s2.0-12944284651 (Pubitemid 40175788)
29. Matsuo K., Tang S. H., Sharifi B., Rubin S. A., Schreck R., Fagin J. A., Growth factor production by human thyroid carcinoma cells: abundant expression of a platelet-derived growth factor-B-like protein by a human papillary carcinoma cell line. Journal of Clinical Endocrinology and Metabolism 1993 77 4 996 1004 2-s2.0-0027365125 10.1210/jc.77.4.996 (Pubitemid 23301476)
30. Cerrato A., De Falco V., Santoro M., Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. Journal of Molecular Endocrinology 2009 43 4 143 155 2-s2.0-70450184514 10.1677/JME-09-0024
31. Harrison D. J., Hooper M. L., Armstrong J. F., Clarke A. R., Effects of heterozygosity for the Rb-1(t19neo) allele in the mouse. Oncogene 1995 10 8 1615 1620 2-s2.0-0028988697
32. Williams B. O., Remington L., Albert D. M., Mukai S., Bronson R. T., Jacks T., Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics 1994 7 4 480 484 2-s2.0-0028136594 10.1038/ng0894-480 (Pubitemid 24308333)
33. Harvey M., Vogel H., Lee E. Y. H. P., Bradley A., Donehower L. A., Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Research 1995 55 5 1146 1151 2-s2.0-0028937476
34. Coxon A. B., Ward J. M., Geradts J., Otterson G. A., Zajac-Kaye M., Kaye F. J., RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 1998 17 12 1625 1628 2-s2.0-0032563945 (Pubitemid 28472767)
35. Joshi P. P., Kulkarni M. V., Yu B. K., Smith K. R., Norton D. L., Veelen W. V., Höppener J. W. M., Franklin D. S., Simultaneous downregulation of CDK inhibitors p18Ink4c and p27Kip1 is required for MEN2A-RET-mediated mitogenesis. Oncogene 2007 26 4 554 570 2-s2.0-33846476858 10.1038/sj.onc. 1209811 (Pubitemid 46160969)
36. Segouffin-Cariou C., Billaud M., Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. Journal of Biological Chemistry 2000 275 5 3568 3576 2-s2.0-0034603172 10.1074/jbc.275.5.3568 (Pubitemid 30083066)
37. Pitt S. C., Chen H., The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery 2008 144 5 721 724 2-s2.0-54549114194 10.1016/j.surg.2008.06.028
38. Kouvaraki M. A., Liakou C., Paraschi A., Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery 2011 150 6 1258 1265 10.1016/j.surg.2011.09.022
39. Asai N., Murakami H., Iwashita T., Takahashi M., A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins. Journal of Biological Chemistry 1996 271 30 17644 17649 2-s2.0-0029893933 10.1074/jbc.271.30.17644 (Pubitemid 26250733)
40. Murakami H., Iwashita T., Asai N., Shimono Y., Iwata Y., Kawai K., Takahashi M., Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by Ret with the MEN 2B mutation. Biochemical and Biophysical Research Communications 1999 262 1 68 75 2-s2.0-0033584474 10.1006/bbrc.1999.1186 (Pubitemid 29412625)
41. Salvatore D., Melillo R. M., Monaco C., Visconti R., Fenzi G., Vecchio G., Fusco A., Santoro M., Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Research 2001 61 4 1426 1431 2-s2.0-0035866411 (Pubitemid 34292568)
42. Pelicci G., Troglio F., Bodini A., Melillo R. M., Pettirossi V., Coda L., De Giuseppe A., Santoro M., Pelicci P. G., The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Molecular and Cellular Biology 2002 22 20 7351 7363 2-s2.0-0036788763 10.1128/MCB.22.20.7351-7363.2002
43. Sansal I., Sellers W. R., The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology 2004 22 14 2954 2963 2-s2.0-4344602002 10.1200/JCO.2004.02.141 (Pubitemid 41079915)
44. Zbuk K. M., Eng C., Cancer phenomics: RET and PTEN as illustrative models. Nature Reviews Cancer 2007 7 1 35 45 2-s2.0-33845875992 10.1038/nrc2037 (Pubitemid 46020845)
45. Yuan T. L., Cantley L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008 27 41 5497 5510 2-s2.0-51849111556 10.1038/onc.2008.245
46. Rapa I., Saggiorato E., Giachino D., Palestini N., Orlandi F., Papotti M., Volante M., Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2011 96 7 2146 2153 2-s2.0-79960094269 10.1210/jc.2010-2655
47. Tamburrino A., Molinolo A. A., Salerno P., Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clinical Cancer Research 2012 18 13 3532 3540 10.1158/1078-0432.CCR-11-2700
48. Grozinsky-Glasberg S., Rubinfeld H., Nordenberg Y., Gorshtein A., Praiss M., Kendler E., Feinmesser R., Grossman A. B., Shimon I., The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Molecular and Cellular Endocrinology 2010 315 1-2 87 94 2-s2.0-71849090738 10.1016/j.mce.2009.09.027
49. Klubo-Gwiezdzinska J., Jensen K., Costello J., Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocrine Related Cancer 2012 19 3 447 456 10.1530/ERC-12-0046
50. Bockhorn M., Frilling A., Kalinin V., Schroder S., Broelsch C. E., Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. Experimental and Clinical Endocrinology and Diabetes 2000 108 1 49 53 2-s2.0-0034101848 (Pubitemid 30160435)
51. Schulten H. J., Al-Maghrabi J., Al-Ghamdi K., Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Research 2011 31 12 4179 4183
52. Ciampi R., Mian C., Fugazzola L., Evidence of a low prevalence of Ras mutations in a large medullary thyroid cancer series. Thyroid 2013 23 1 50 57
53. Moura M. M., Cavaco B. M., Pinto A. E., Leite V., High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2011 96 5 E863 E868 2-s2.0-79955669404 10.1210/jc.2010-1921
54. Agrawal N., Jiao Y., Sausen M., Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism 2012 10.1210/jc.2012-2703
55. Boichard A., Croux L., Al Ghuzlan A., Somatic Ras mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. The Journal of Clinical Endocrinology and Metabolism 2012 97 10 E2031 E2035 10.1210/jc.2012-2092
56. Weinberg R. A., The cat and mouse games that genes, viruses, and cells play. Cell 1997 88 5 573 575 2-s2.0-0030900653 10.1016/S0092-8674(00)81897-8 (Pubitemid 27152398)
57. Santarpia L., Lippman S. M., El-Naggar A. K., Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 2012 16 1 103 119 10.1517/14728222.2011.645805
58. Carson E. B., McMahon M., Baylin S. B., Nelkin B. D., Ret gene silencing is associated with raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Research 1995 55 10 2048 2052 2-s2.0-0029006925
59. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T., Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993 259 5104 85 88 2-s2.0-0027905014 (Pubitemid 23122749)
60. Wood K. W., Qi H., D'Arcangelo G., Armstrong R. C., Roberts T. M., Halegoua S., The cytoplasmic raf oncogene induces a neuronal phenotype in PC12 cells: a potential role for cellular raf kinases in neuronal growth factor signal transduction. Proceedings of the National Academy of Sciences of the United States of America 1993 90 11 5016 5020 2-s2.0-0027164311 (Pubitemid 23182966)
61. Park J. I., Strock C. J., Ball D. W., Nelkin B. D., The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Molecular and Cellular Biology 2003 23 2 543 554 2-s2.0-0037221065 10.1128/MCB.23.2.543-554.2003 (Pubitemid 36050548)
62. Arthan D., Hong S. K., Park J. I., Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Letters 2010 297 1 31 41 2-s2.0-77956229707 10.1016/j.canlet. 2010.04.021
63. Kunnimalaiyaan M., Vaccaro A. M., Ndiaye M. A., Chen H., Inactivation of glycogen synthase kinase-3 β a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Molecular Cancer Therapeutics 2007 6 3 1151 1158 2-s2.0-34147168760 10.1158/1535-7163.MCT- 06-0665 (Pubitemid 46554586)
64. Gujral T. S., Van Veelen W., Richardson D. S., Myers S. M., Meens J. A., Acton D. S., Duñach M., Elliott B. E., Höppener J. W. M., Mulligan L. M., A novel RET kinase- β -catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Research 2008 68 5 1338 1346 2-s2.0-40449086887 10.1158/0008-5472.CAN-07-6052 (Pubitemid 351346840)
65. Ludwig L., Kessler H., Wagner M., Hoang-Vu C., Dralle H., Adler G., Böhm B. O., Schmid R. M., Nuclear factor- B is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Research 2001 61 11 4526 4535 2-s2.0-0035354187 (Pubitemid 32685784)
66. Santarpia L., Bottai G., Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers. Current Pharmaceutical Design 2012 19
67. Lorusso P. M., Eder J. P., Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opinion on Investigational Drugs 2008 17 7 1013 1028 2-s2.0-48249137667 10.1517/13543784.17.7.1013
68. Walsh S., Prichard R., Hill A. D., Emerging therapies for thyroid carcinoma. Surgeon 2012 10 1 53 58 10.1016/j.surge.2011.08.004
69. Vitagliano D., De Falco V., Tamburrino A., Coluzzi S., Troncone G., Chiappetta G., Ciardiello F., Tortora G., Fagin J. A., Ryan A. J., Carlomagno F., Santoro M., The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine-Related Cancer 2011 18 1 1 11 2-s2.0-79251531655 10.1677/ERC-09-0292
70. Stommel J. M., Kimmelman A. C., Ying H., Nabioullin R., Ponugoti A. H., Wiedemeyer R., Stegh A. H., Bradner J. E., Ligon K. L., Brennan C., Chin L., DePinho R. A., Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007 318 5848 287 290 2-s2.0-35348822482 10.1126/science.1142946 (Pubitemid 47574858)
71. Ocana A., Amir E., Seruga B., Pandiella A., Do we have to change the way targeted drugs are developed? Journal of Clinical Oncology 2010 28 24 e420 e421 2-s2.0-77956255939 10.1200/JCO.2010.28.9918
72. van Amerongen R., Berns A., Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape. Cancer Cell 2008 13 1 5 7 2-s2.0-37349004468 10.1016/j.ccr.2007.12.019 (Pubitemid 350309746)
73. Knight Z. A., Lin H., Shokat K. M., Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 2010 10 2 130 137 2-s2.0-75149130051 10.1038/nrc2787
74. Sherman S. I., Targeted therapies for thyroid tumors. Modern Pathology 2011 24 2 S44 S52 2-s2.0-79953329570 10.1038/modpathol.2010.165
75. Herbst R. S., Heymach J. V., O'Reilly M. S., Onn A., Ryan A. J., Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs 2007 16 2 239 249 2-s2.0-33846850223 10.1517/13543784.16.2.239 (Pubitemid 46206638)
76. Carlomagno F., Guida T., Anaganti S., Vecchio G., Fusco A., Ryan A. J., Billaud M., Santoro M., Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004 23 36 6056 6063 2-s2.0-4444273158 10.1038/sj.onc.1207810 (Pubitemid 39178858)
77. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M. R., Aldinucci D., Pinto A., Normanno N., The role of the EGFR signaling in tumor microenvironment. Journal of Cellular Physiology 2008 214 3 559 567 2-s2.0-38449087414 10.1002/jcp.21260 (Pubitemid 351224199)
78. Wells S. A. Jr., Gosnell J. E., Gagel R. F., Moley J., Pfister D., Sosa J. A., Skinner M., Krebs A., Vasselli J., Schlumberger M., Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology 2010 28 5 767 772 2-s2.0-77649214078 10.1200/JCO.2009.23.6604
79. Robinson B. G., Paz-Ares L., Krebs A., Vasselli J., Haddad R., Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2010 95 6 2664 2671 2-s2.0-77954478933 10.1210/jc.2009-2461
80. Commander H., Whiteside G., Perry C., Vandetanib: first global approval. Drugs 2011 71 10 1355 1365 10.2165/11595310-000000000-00000
81. Wells S. A. Jr., Robinson B. G., Gagel R. F., Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 30 2 134 141 10.1200/JCO.2011.35.5040
82. Kurzrock R., Cohen E. E., Sherman S. I., Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study with XL-184 (BMS, 907351), an oral inhibitor of MET, VEGFR2, and RET. Journal of Clinical Oncology 2010 28 Abstract 5502 15S
83. Kurzrock R., Sherman S. I., Ball D. W., Forastiere A. A., Cohen R. B., Mehra R., Pfister D. G., Cohen E. E. W., Janisch L., Nauling F., Hong D. S., Ng C. S., Ye L., Gagel R. F., Frye J., Müller T., Ratain M. J., Salgia R., Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 2011 29 19 2660 2666 2-s2.0-79959936054 10.1200/JCO.2010.32.4145
84. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S. M., Santoro M., BAY 43-9006 inhibition of oncogenic RET mutants. Journal of the National Cancer Institute 2006 98 5 326 334 2-s2.0-33644747449 10.1093/jnci/djj069 (Pubitemid 43338212)
85. Lam E. T., Ringel M. D., Kloos R. T., Prior T. W., Knopp M. V., Liang J., Sammet S., Hall N. C., Wakely P. E., Vasko V. V., Saji M., Snyder P. J., Wei L., Arbogast D., Collamore M., Wright J. J., Moley J. F., Villalona-Calero M. A., Shah M. H., Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 2010 28 14 2323 2330 2-s2.0-77952468875 10.1200/JCO.2009.25.0068
86. Frank-Raue K., Ganten M., Kreissl M. C., Raue F., Rapid response to sorafenib in metastatic medullary thyroid carcinoma. Experimental and Clinical Endocrinology and Diabetes 2011 119 3 151 155 2-s2.0-79952101581 10.1055/s-0030-1262836
87. Capdevila J., Iglesias L., Halperin I., Sorafenib in patients (pts) with advanced thryroid carcinoma (TC): a compassionate use program. Journal of Clinical Oncology 2010 28 Abstract 5590 15S
88. Carr L. L., Mankoff D. A., Goulart B. H., Eaton K. D., Capell P. T., Kell E. M., Bauman J. E., Martins R. G., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 2010 16 21 5260 5268 2-s2.0-78049462514 10.1158/1078-0432.CCR-10-0994
89. Ravaud A., De La Fouchardière C., Asselineau J., Delord J. P., Cao C. D. O., Niccoli P., Rodien P., Klein M., Catargi B., Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010 15 2 212 213 2-s2.0-77649112149 10.1634/theoncologist.2009-0303
90. Polverino A., Coxon A., Starnes C., Diaz Z., DeMelfi T., Wang L., Bready J., Estrada J., Cattley R., Kaufman S., Chen D., Gan Y., Kumar G., Meyer J., Neervannan S., Alva G., Talvenheimo J., Montestruque S., Tasker A., Patel V., Radinsky R., Kendall R., AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research 2006 66 17 8715 8721 2-s2.0-33749000911 10.1158/0008-5472.CAN-05-4665 (Pubitemid 44449188)
91. Schlumberger M. J., Elisei R., Bastholt L., Wirth L. J., Martins R. G., Locati L. D., Jarzab B., Pacini F., Daumerie C., Droz J. P., Eschenberg M. J., Sun Y. N., Juan T., Stepan D. E., Sherman S. I., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of Clinical Oncology 2009 27 23 3794 3801 2-s2.0-68949108390 10.1200/JCO.2008.18.7815
92. Coxon A., Bready J., Kaufman S., Anti-tumor activity of motesanib in a medullary thyroid cancer model. Journal of Endocrinological Investigation 2012 35 2 181 190
93. de Groot J. W. B., Zonnenberg B. A., Van Ufford-Mannesse P. Q., De Vries M. M., Links T. P., Lips C. J. M., Voest E. E., A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 9 3466 3469 2-s2.0-34548749440 10.1210/jc.2007-0649 (Pubitemid 47435321)
94. Verbeek H. H. G., Alves M. M., De Groot J. W. B., Osinga J., Plukker J. T. M., Links T. P., Hofstra R. M. W., The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 2011 96 6 E991 E995 2-s2.0-79956290905 10.1210/jc.2010-2381
95. Massart C., Gibassier J., Lucas C., Pourquier P., Robert J., Doxorubicine resistance modulation by ciclosporin a and verapamil in five human cell lines or medullary thyroid cancer. Bulletin du Cancer 1996 83 1 39 45 2-s2.0-0029717691
96. Breier A., Barančík M., Sulová Z., Uhrík B., P-glycoprotein-Implications of metabolism of neoplastic cells and cancer therapy. Current Cancer Drug Targets 2005 5 6 457 468 2-s2.0-23844521998 10.2174/1568009054863636 (Pubitemid 41176180)
97. Patel V. A., Dunn M. J., Sorokin A., Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. Journal of Biological Chemistry 2002 277 41 38915 38920 2-s2.0-0037064039 10.1074/jbc.M206855200 (Pubitemid 35154756)
98. Zatelli M. C., Luchin A., Piccin D., Tagliati F., Bottoni A., Vignali C., Bondanelli M., Degli Uberti E. C., Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. Journal of Clinical Endocrinology and Metabolism 2005 90 10 5754 5760 2-s2.0-26244433089 10.1210/jc.2005-1362 (Pubitemid 41415487)
99. Vivaldi A., Ciampi R., Tacito A., Colecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Molecular and Cellular Endocrinology 2012 355 1 41 48 10.1016/j.mce.2012.01.015
100. Kunnimalaiyaan M., Ndiaye M., Chen H., Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006 140 6 1009 1015 2-s2.0-33845626635 10.1016/j.surg.2006.06.040 (Pubitemid 44940811)
101. Iwase Y., Maitani Y., Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. Biological & Pharmaucetical Bulletin 2012 35 6 975 979
102. Jin N., Jiang T., Rosen D. M., Nelkin B. D., Ball D. W., Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clinical Cancer Research 2011 17 20 6482 6489 10.1158/1078-0432.CCR-11-0933
103. Couto J. P., Almeida A., Daly L., Sobrinho-Simões M., Bromberg J. F., Soares P., AZD1480 blocks growth and tumorigenesis of RET-activated thryoid cancer cell lines. PloS One 2012 7 10 E46869
104. Papotti M., Kumar U., Volante M., Pecchioni C., Patel Y. C., Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clinical Endocrinology 2001 54 5 641 649 2-s2.0-0035726431 10.1046/j.1365-2265.2001.01175.x (Pubitemid 34208908)
105. Mato E., Matías-Guiu X., Chico A., Webb S. M., Cabezas R., Berná L., De Leiva A., Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1998 83 7 2417 2420 2-s2.0-0031784575 10.1210/jc.83.7.2417 (Pubitemid 28503040)
106. Mitsiades C. S., McMillin D., Kotoula V., Poulaki V., McMullan C., Negri J., Fanourakis G., Tseleni-Balafouta S., Ain K. B., Mitsiades N., Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Journal of Clinical Endocrinology and Metabolism 2006 91 10 4013 4021 2-s2.0-33748744702 10.1210/jc.2005-2472 (Pubitemid 44536879)
107. Schott M., Seissler J., Lettmann M., Fouxon V., Scherbaum W. A., Feldkamp J., Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. Journal of Clinical Endocrinology and Metabolism 2001 86 10 4965 4969 2-s2.0-0034750683 10.1210/jc.86.10.4965 (Pubitemid 33020550)
108. Wuttke M., Papewalis C., Meyer Y., Kessler C., Jacobs B., Willenberg H. S., Schinner S., Kouatchoua C., Baehring T., Scherbaum W. A., Schott M., Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma. Endocrinology 2008 149 11 5627 5634 2-s2.0-54349094277 10.1210/en.2008-0631
109. Papewalis C., Wuttke M., Jacobs B., Domberg J., Willenberg H., Baehring T., Cupisti K., Raffel A., Chao L., Fenk R., Seissler J., Scherbaum W. A., Schott M., Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Hormone and Metabolic Research 2008 40 2 108 116 2-s2.0-40549114986 10.1055/s-2007-1022565 (Pubitemid 351363421)
110. Bachleitner-Hofmann T., Friedl J., Hassler M., Hayden H., Dubsky P., Sachet M., Rieder E., Pfragner R., Brostjan C., Riss S., Niederle B., Gnant M., Stift A., Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncology Reports 2009 21 6 1585 1592 2-s2.0-67649910150 10.3892/or-00000391
111. Kraeber-Bodéré F., Bodet-Milin C., Niaudet C., Saï-Maurel C., Moreau A., Faivre-Chauvet A., Thomare P., Deleris G., Estieu-Gionnet K., Bikfalvi A., Barbet J., Paris F., Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. Journal of Nuclear Medicine 2010 51 4 624 631 2-s2.0-77950949514 10.22967/jnumed.109. 070714
112. Salaun P. Y., Bodet-Milin C., Frampas E., Oudoux A., Saï-Maurel C., Faivre-Chauvet A., Barbet J., Paris F., Kraeber-Bodéré F., Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer 2010 116 4 1053 1058 2-s2.0-76249125907 10.1002/cncr.24792
113. Catalano M. G., Fortunati N., Boccuzzi G., Epigenetics modifications and therapeutic prospects in human thyroid cancer. Frontiers in Endocrinology 2012 3 40 10.3389/fendo.2012.00040
114. Romei C., Mariotti S., Fugazzola L., Taccaliti A., Pacini F., Opocher G., Mian C., Castellano M., Uberti E. D., Ceccherini I., Cremonini N., Seregni E., Orlandi F., Ferolla P., Puxeddu E., Giorgino F., Colao A., Loli P., Bondi F., Cosci B., Bottici V., Cappai A., Pinna G., Persani L., Uberta V., Boscaro M., Castagna M. G., Cappelli C., Zatelli M. C., Faggiano A., Francia G., Brandi M. L., Falchetti A., Pinchera A., Elisei R., Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology 2010 163 2 301 308
115. Zhu W., Hai T., Ye L., Cote G. J., Medullary thyroid carcinoma cell lines contain a self-renewing CD133 + population that is dependent on Ret proto-oncogene activity. Journal of Clinical Endocrinology and Metabolism 2010 95 1 439 444 2-s2.0-75149138258 10.1210/jc.2009-1485